Dr. David Horsley
Research Fellow
Applied Medicine
Institute of Medical Sciences
Postal address:
Polwarth Building, Foresterhill, Aberdeen
United Kingdom
Organisation: d.horsley@abdn.ac.uk

Research outputs

Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease
Frahm, S., Melis, V., Horsley, D., Rickard, J., Riedel, G., Fadda, P., Scherma, M., Harrington, C., Wischik, C., Theuring, F. & Schwab, K., 26 Feb 2018, In: Behavioural Brain Research. 339, p. 153-168 16 p.

A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy
Schwab, K., Frahm, S., Horsley, D., Rickard, J. E., Melis, V., Goatman, E. A., Magbagbeolu, M., Douglas, M., Leith, M. G. , Baddeley, T. C., Storey, J. M. D., Riedel, G., Wischik, C. M., Harrington, C. R. & Theuring, F., 10 Jan 2018, In: Frontiers in Molecular Neuroscience. 10, 15 p., 447.

Assays for the Screening and Characterization of Tau Aggregation Inhibitors
Rickard, J. E., Horsley, D., Wischik, C. M. & Harrington, C. R., 15 Dec 2016, *Tau Protein: Methods and Protocols*. Smet-Nocca, C. (ed.). Springer , Vol. 1523. p. 129-140 12 p. (Methods in Molecular Biology; vol. 1523).

Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration
Melis, V., Zabke, C., Stamer, K., Magbagbeolu, M., Schwab, K., Marshall, P., Weh, R. W., Bachmann, S., Deiana, S., Moreau, P. H., Davidson, K., Harrington, K. A., Rickard, J. E., Horsley, D., Garman, R., Mazurkiewicz, M., Niewiadomska, G., Wischik, C. M., Harrington, C. R., Riedel, G. & 1 others, Theuring, F., Jun 2015, In: Cellular and Molecular Life Sciences. 72, 11, p. 2199-2222 24 p.

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models
Melis, V., Magbagbeolu, M., Rickard, J. E., Horsley, D., Davidson, K., Harrington, K. A., Goatman, K., Goatman, E. A., Deiana, S., Close, S. P., Zabke, C., Stamer, K., Dietze, S., Schwab, K., Storey, J. M. D., Harrington, C. R., Wischik, C. M. , Theuring, F. & Riedel, G., Jun 2015, In: Behavioural Pharmacology. 26, 4, p. 353-368 16 p.

Cellular Models of Aggregation-Dependent Template-Directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer's Disease
Harrington, C. R., Storey, J. M. D., Clunas, S., Harrington, K. A., Horsley, D., Ishaq, A., Kemp, S. J., Larch, C. P., Marshall, C., Nicoll, S. L., Rickard, J. E., Simpson, M., Sinclair, J. P., Storey, L. J. & Wischik, C. M., 24 Apr 2015, In: The Journal of Biological Chemistry. 290, 17, p. 10862-10875 14 p.

Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease
Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R. & Wischik, C. M., Jan 2015, In: Journal of Pharmacology and Experimental Therapeutics. 352, 1, p. 110-118 9 p.

New phenothiazine diaminium compounds are tau protein aggregation inhibitors, useful to treat e.g. Alzheimer's disease, Pick's disease, progressive supranuclear palsy, frontotemporal dementia and frontotemporal lobar degeneration syndromes
Baddeley, T., Clunas, S., Harrington, C. R., Horsley, D., Ishaq, A., Khan, K., Loh, Y. S., Marshall, C., Rickard, J. E., Simpson, M., Sinclair, J. P., Storey, J. M. D., Williamson, C., Wischik, C. M. & Wood, B. A., 16 Aug 2012, Patent No. WO2012107706-A1, Priority date 11 Feb 2011

3,7-diamino-10H-phenothiazine salts and their use: WO2007110627
Wischik, C. M., Rickard, J. E., Harrington, C. R., Horsley, D., Storey, J. M. D., Marshall, C., Sinclair, J. P. & Baddeley, T., 15 Feb 2011, Patent No. US7,888,350

3,6-Disubstituted xanthylium salts
Clunas, S., Storey, J. M. D., Horsley, D., Rickard, J. E., Harrington, C. R. & Wischik, C. M., 17 Jun 2010, IPC No. WO2010/067078

Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC): methods of treatment of a tauopathy condition comprising the use of thioninium compounds
Wischik, C. M., Rickard, J. E., Harrington, C. R., Horsley, D., Storey, J. M. D., Marshall, C. & Sinclair, J. P., 15 Jun 2010, Patent No. US7,737,138

Ligands for aggregated tau molecules: WO2010034982
Kemp, S. J., Storey, J. M. D., Rickard, J. E., Harrington, C. R., Horsley, D., Wischik, C. M., Clunas, S. & Heinrich, T., 1 Apr 2010, Patent No. WO2010/034982

Inhibitors of protein aggregation: WO2007110629
Wischik, C. M., Rickard, J. E., Horsley, D. & Harrington, C. R., 4 Oct 2007, Patent No. WO2007110629

Naphthoquinone-type inhibitors of protein aggregation
Wischik, C. M., Horsley, D., Rickard, J. E. & Harrington, C. R., 2003, Patent No. WO 03/007933; published 30.01.03

Materials and methods relating to protein aggregation in neurodegenerative disease: WO2002059150
Wischik, C. M., Rickard, J. E., Horsley, D. & Harrington, C. R., 1 Aug 2002, Patent No. PCT/GB02/00005; published 1.08.02

Materials and methods relating to protein aggregation in neurodegenerative disease: WO2002055720
Wischik, C. M., Horsley, D., Rickard, J. E. & Harrington, C. R., 2002, Patent No. PCT/GB02/00153; published 18.07.02

Neurofibrillary labels
Wischik, C. M., Harrington, C. R., Rickard, J. E. & Horsley, D., 2002, Patent No. WO 02/075318 A2; published 26.09.02

Impacts

Discovery and commercialisation of an entirely new drug for the treatment of Alzheimer's disease
Claude Wischik (Participant), Charles Harrington (Participant), John Storey (Participant), Janet Rickard (Participant), David Horsley (Participant), Thomas Baddeley (Participant), Steven Kemp (Participant), James Sinclair (Participant), Claudia Zabke (Participant), F. Theuring (Participant), F Stamer (Participant) & C Marshall (Participant)